Merck KGaA is offering research grants to stimulate innovative research in challenging areas of future importance. Grants of 100,000 to 500,000 euro (approximately $110,000 to $550,000) for up to three years are available for the focus area of pandemic preparedness and fighting new emerging viral infectious diseases. This opportunity is open to U.S.-based researchers.
MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers. The initial grant amount is $10,000, with the possibility for larger awards in later phases.
The Distance Learning and Telemedicine program helps rural communities use the unique capabilities of telecommunications to connect to each other and to the world, overcoming the effects of remoteness and low population density.
It is our intent to support educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19, as well as provide support to hospitals or healthcare systems so that they may evaluate and improve their systems-of-care for COVID-19 patients. We are releasing this RFP to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolv
The Peer Reviewed Medical Research Program (PRMRP) offers the following three opportunities for Emerging Viral Diseases and Respiratory Health with a focus on COVID-19 research. (1) Clinical Trial Award (W81XWH-20-PRMRP-CTA-COV) - preproposal due June 8, 2020 full proposal due June 22, 2020, (2) Investigator Initiated Research Award (W81XWH-20-PRMRP-IIRA-COV) - preproposal due May 28, 2020 full proposal due June 12, 2020, (3) Technology/Therapeutic Development Award (W81XWH-20-PRMRP-TTDA-COV) - preproposal due May 28, 2020 full proposal due June 12, 2020.
Now seeking abstract submissions for the following: 4.1-B Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus; 4.1-C: Diagnostic Tests for detection of COVID-19 disease; 4.3 COVID-19 Vaccine; 4.4 Advanced Manufacturing Technologies. The total Government share of funding, including options, of any project awarded under this EZ-BAA shall be less than $750,000.
BAA for DARPA's Biological Technologies Office
NEH invites applications from eligible organizations seeking support for at-risk humanities positions and projects that have been impacted by the coronavirus. Through this funding opportunity, NEH will award grants to museums, libraries and archives, historic sites, independent research institutions, professional organizations, colleges and universities, and other cultural organizations across the country to help these entities continue to advance their mission during the interruption of their operations due to the coronavirus pandemic.
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals.